Drugs / bleselumab
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01582399 | Feb → Sep 2012 | — | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01279538 | Nov 2010 → Jan 2012 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT02921789 | May 2017 → Dec 2020 | primary focal segmental glomerulosclerosis | Astellas Pharma Global Development, Inc. | Completed | Missed primary |
| Phase 2 | NCT01780844 | Mar 2013 → Jun 2014 | — | Astellas Pharma Global Development, Inc. | Completed | Mixed |
| Phase 2 | NCT01585233 | Apr 2012 → Jun 2014 | psoriasis | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bleselumab | “anti-CD40 monoclonal antibody bleselumab (ASKP1240)” PMID 31509331 ↗ Oct 2019 |
| Known as | ASKP1240 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01585233 ↗ |
| Action | Inhibit | “anti-CD40 antagonistic monoclonal antibody” PMID 39042770 ↗ Jul 2024 |
| Modality | Monoclonal antibody | “a fully human, anti-CD40 monoclonal antibody” PMID 31397943 ↗ Sep 2019 |
| Route | Intravenous | “Intravenous (IV) infusion” NCT01279538 ↗ |
| Target | CD40 | “anti-CD40 monoclonal antibody” PMID 31397943 ↗ Sep 2019 |